269 East Grand Ave.
South San Francisco, CA 94080
April 9, 2020
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Chris Edwards, Office of Life Sciences
Re: | Cortexyme, Inc. Registration Statement on Form S-1 Filed April 7, 2020 File No. 333-237594 REQUEST FOR ACCELERATION OF EFFECTIVENESS |
Acceleration Request
Requested Date: | April 13, 2020 | |
Requested Time: | 4:00 p.m. Eastern Time |
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Cortexyme, Inc. (the Company) hereby requests that the Securities and Exchange Commission (the Commission) take appropriate action to declare the Companys Registration Statement on Form S-1 (File No. 333-237594) effective at the Requested Date and Requested Time set forth above or as soon thereafter as practicable.
The Company hereby authorizes Niki Fang, who is an attorney with the Companys outside legal counsel, Orrick, Herrington & Sutcliffe LLP, to orally modify or withdraw this request for acceleration.
The Company requests that it be notified of such effectiveness by a telephone call to Ms. Fang at (415) 773-5540.
[Signature page follows]
Sincerely, | ||
CORTEXYME, INC. | ||
By: | /s/ Christopher Lowe | |
Name: Christopher Lowe | ||
Title: Chief Financial Officer |
cc: | Casey C. Lynch, Cortexyme Inc. |
Ted Monohon, Cortexyme Inc.
Scott M. Iyama, Esq., Orrick, Herrington & Sutcliffe LLP
Niki Fang, Esq., Orrick, Herrington & Sutcliffe LLP